I L Andrulis

Summary

Affiliation: Samuel Lunenfeld Research Institute
Country: Canada

Publications

  1. pmc A genome-wide linkage study of mammographic density, a risk factor for breast cancer
    Celia M T Greenwood
    Program in Genetics and Genome Biology, The Hospital for Sick Children, 101 College Street, East Tower, Toronto, ON M5G 1L7, Canada
    Breast Cancer Res 13:R132. 2011
  2. pmc Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors
    Anita L Bane
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada
    Breast Cancer Res Treat 117:183-91. 2009
  3. pmc Rare variants in the ATM gene and risk of breast cancer
    David E Goldgar
    Department of Dermatology, University of Utah School of Medicine, 30 N 1900 E, Salt Lake City, UT 84132 2101, USA
    Breast Cancer Res 13:R73. 2011
  4. pmc Analysis of incidence and prognostic factors for ipsilateral breast tumour recurrence and its impact on disease-specific survival of women with node-negative breast cancer: a prospective cohort study
    Michelle K Nottage
    Royal Brisbane Hospital, Herston Road, Herston, Queensland 4029, Australia
    Breast Cancer Res 8:R44. 2006
  5. pmc Genomics and premalignant breast lesions: clues to the development and progression of lobular breast cancer
    Teresa L Mastracci
    Department of Cancer Genetics and Developmental Biology, British Columbia Cancer Research Centre, West 10th Ave, Vancouver, BC, Canada V5Z 1L3
    Breast Cancer Res 9:215. 2007
  6. pmc The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer
    Esther M John
    Clinical and Genetic Epidemiology Research Branch, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland, USA
    Breast Cancer Res 6:R375-89. 2004
  7. pmc Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk
    Ummiye V Onay
    Fred A, Litwin Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
    BMC Cancer 8:6. 2008
  8. pmc The interaction of PP1 with BRCA1 and analysis of their expression in breast tumors
    Sherry L Winter
    Fred A, Litwin Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
    BMC Cancer 7:85. 2007
  9. pmc Polymorphisms cMyc-N11S and p27-V109G and breast cancer risk and prognosis
    Jane C Figueiredo
    Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
    BMC Cancer 7:99. 2007
  10. pmc SNP-SNP interactions in breast cancer susceptibility
    Venüs Ummiye Onay
    Fred A Litwin Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
    BMC Cancer 6:114. 2006

Collaborators

Detail Information

Publications37

  1. pmc A genome-wide linkage study of mammographic density, a risk factor for breast cancer
    Celia M T Greenwood
    Program in Genetics and Genome Biology, The Hospital for Sick Children, 101 College Street, East Tower, Toronto, ON M5G 1L7, Canada
    Breast Cancer Res 13:R132. 2011
    ..Mammographic breast density is a highly heritable (h2 > 0.6) and strong risk factor for breast cancer. We conducted a genome-wide linkage study to identify loci influencing mammographic breast density (MD)...
  2. pmc Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors
    Anita L Bane
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada
    Breast Cancer Res Treat 117:183-91. 2009
    ..To elucidate novel genes involved in these two spectra of breast tumorigenesis we performed global gene expression analysis on breast tumors from germline BRCA1 and BRCA2 mutation carriers...
  3. pmc Rare variants in the ATM gene and risk of breast cancer
    David E Goldgar
    Department of Dermatology, University of Utah School of Medicine, 30 N 1900 E, Salt Lake City, UT 84132 2101, USA
    Breast Cancer Res 13:R73. 2011
    ..However, the magnitude of risk and the subset of variants that are pathogenic for breast cancer remain unresolved...
  4. pmc Analysis of incidence and prognostic factors for ipsilateral breast tumour recurrence and its impact on disease-specific survival of women with node-negative breast cancer: a prospective cohort study
    Michelle K Nottage
    Royal Brisbane Hospital, Herston Road, Herston, Queensland 4029, Australia
    Breast Cancer Res 8:R44. 2006
    ....
  5. pmc Genomics and premalignant breast lesions: clues to the development and progression of lobular breast cancer
    Teresa L Mastracci
    Department of Cancer Genetics and Developmental Biology, British Columbia Cancer Research Centre, West 10th Ave, Vancouver, BC, Canada V5Z 1L3
    Breast Cancer Res 9:215. 2007
    ..We highlight studies utilizing genomic approaches and describe how these investigations have furthered our understanding of the complexity of premalignant breast lesions...
  6. pmc The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer
    Esther M John
    Clinical and Genetic Epidemiology Research Branch, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland, USA
    Breast Cancer Res 6:R375-89. 2004
    ....
  7. pmc Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk
    Ummiye V Onay
    Fred A, Litwin Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
    BMC Cancer 8:6. 2008
    ..Several studies have also shown the relationship between estrogen and cell cycle progression through activation of CCND1 transcription...
  8. pmc The interaction of PP1 with BRCA1 and analysis of their expression in breast tumors
    Sherry L Winter
    Fred A, Litwin Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
    BMC Cancer 7:85. 2007
    ..Additionally, detection of changes in the expression levels of BRCA1 and its interacting proteins in primary human breast tumors may further illuminate their role in the development of breast cancer...
  9. pmc Polymorphisms cMyc-N11S and p27-V109G and breast cancer risk and prognosis
    Jane C Figueiredo
    Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
    BMC Cancer 7:99. 2007
    ..In this study, we focus on a rare non-synonymous polymorphism in cMyc (N11S) and a common polymorphism in p27 (V109G) and determine their role in risk and prognosis using data collected from the Ontario Breast Cancer Family Registry...
  10. pmc SNP-SNP interactions in breast cancer susceptibility
    Venüs Ummiye Onay
    Fred A Litwin Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
    BMC Cancer 6:114. 2006
    ..However, polygenic models suggest that multiple commonly occurring low to modestly penetrant SNPs of cancer related genes might have a greater effect on a disease when considered in combination...
  11. ncbi request reprint neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group
    I L Andrulis
    Samuel Lunenfeld Research Institute, Department of Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
    J Clin Oncol 16:1340-9. 1998
    ..Although overexpression has been investigated extensively, this study represents the first prospective assessment of the prognostic value of neu/erbB-2 DNA amplification in a cohort of women with newly diagnosed ANN...
  12. ncbi request reprint Comparison of DNA- and RNA-based methods for detection of truncating BRCA1 mutations
    Irene L Andrulis
    Fred A Litwin Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
    Hum Mutat 20:65-73. 2002
    ..It will continue to be important to use complementary methods for mutational analysis...
  13. doi request reprint Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial
    F P O'Malley
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
    Breast Cancer Res Treat 128:401-9. 2011
    ..The topo 2α protein analysis was exploratory and will require further validation...
  14. pmc p53 missense but not truncation mutations are associated with low levels of p21(CIP1/WAF1) mRNA expression in primary human sarcomas
    S Mousses
    Samuel Lunenfeld Research Institute, Department of Laboratory Medicine and Pathobiology, Mount Sinai Hospital, Toronto, Ontario, Canada
    Br J Cancer 84:1635-9. 2001
    ..The results of this study suggest that different types of p53 mutations can have different effects on the expression of downstream genes such as p21(CIP1/WAF1) in human sarcomas...
  15. ncbi request reprint MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study
    J S Wunder
    Samuel Lunenfeld Research Institute and the University Musculoskeletal Oncology Unit, Mount Sinai Hospital, Toronto, Ontario, Canada
    J Clin Oncol 18:2685-94. 2000
    ..This study represents the first prospective assessment of the prognostic value of MDR1 mRNA expression in patients with newly diagnosed extremity osteosarcoma...
  16. ncbi request reprint Functional characterization of novel presenilin-2 variants identified in human breast cancers
    M D To
    Fred A Litwin Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
    Oncogene 25:3557-64. 2006
    ..Nonetheless, these results collectively suggest that the novel PS-2 alleles described here, especially R71W, affect PS-2 function and may potentially confer a moderate risk of susceptibility to breast cancer...
  17. ncbi request reprint Perceptions of Ashkenazi Jewish breast cancer patients on genetic testing for mutations in BRCA1 and BRCA2
    K A Phillips
    Department of Medical Oncology and Haematology, Princess Margaret Hospital, Toronto, Ontario, Canada
    Clin Genet 57:376-83. 2000
    ..The focus on altruistic factors and those related to perceived psychological benefits of testing is notable...
  18. ncbi request reprint Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: are they prognostically different?
    K A Phillips
    Samuel Lunenfeld Research Institute and Marvelle Koffler Breast Center, Mt Sinai Hospital, and University of Toronto, Toronto, Ontario, Canada
    J Clin Oncol 17:3653-63. 1999
    ..To review the preclinical and clinical studies relevant to the prognosis and prognostic associations of BRCA1- and BRCA2-associated breast carcinomas, with an emphasis on research methodology...
  19. ncbi request reprint Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma
    N Gokgoz
    Fred A. Litwin Center for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
    Cancer 92:2181-9. 2001
    ..The current data indicate that p53 mutations are not late events in osteosarcoma tumor progression, because they are evident before the development of metastases. The inclusion of exons 4 and 10 increased the sensitivity of the analysis...
  20. pmc Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy
    F P O'Malley
    Sunnybrook Odette Cancer Centre, University of Toronto, 2075 Bayview Ave, Toronto, Ontario, Canada
    J Natl Cancer Inst 101:644-50. 2009
    ....
  21. pmc BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients
    H Yazici
    Centre for Cancer Genetics, Department of Pathology and Laboratory Medicine, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Canada
    Br J Cancer 83:737-42. 2000
    ..The BRCA1 5382insC mutation, specific to Ashkenazi and Russian populations, was found twice in our study group, representing a possible founder mutation in the Turkish population...
  22. ncbi request reprint p53 missense mutations in microdissected high-grade ductal carcinoma in situ of the breast
    S J Done
    Department of Laboratory Medicine and Pathobiology and Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, ON, Canada
    J Natl Cancer Inst 93:700-4. 2001
    ..Our finding that p53 mutations can occur before the development of invasive breast cancer, particularly in DCIS of high histologic grade, has potentially important implications for prevention and treatment...
  23. ncbi request reprint Using cancer registry data: agreement in cause-of-death data between the Ontario Cancer Registry and a longitudinal study of breast cancer patients
    D R Brenner
    The Prosserman Centre for Health Research, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, ON
    Chronic Dis Can 30:16-9. 2009
    ..5, 98.8) and a specificity of 88% (95% CI: 79.6, 92.4). The OCR is a valuable tool for epidemiologic studies of breast cancer to acquire adequate and easily attainable cause-of-death information...
  24. pmc Familial posterior fossa brain tumors of infancy secondary to germline mutation of the hSNF5 gene
    M D Taylor
    Arthur and Sonia Labatt Brain Tumor Research Centre, Division of Neurosurgery, Hospital for Sick Children, University of Toronto, Toronto, Canada
    Am J Hum Genet 66:1403-6. 2000
    ..These findings suggest that germline mutations in hSNF5 are associated with a novel autosomal dominant syndrome with incomplete penetrance that predisposes to malignant posterior fossa brain tumors in infancy...
  25. ncbi request reprint Factors affecting distant disease-free survival for primary invasive breast cancer: use of a log-normal survival model
    D R McCready
    Department of Surgical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada
    Ann Surg Oncol 7:416-26. 2000
    ..Invasive breast cancer is a frequently diagnosed disease that now comes with an ever expanding array of therapeutic management options. We assessed the effects of 20 prognostic factors in a multivariate context...
  26. ncbi request reprint The Cooperative Familial Registry for Breast Cancer Studies: design and first year recruitment rates in Ontario
    H J Sutherland
    The Ontario Familial Breast Cancer Registry, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada
    J Clin Epidemiol 54:93-8. 2001
    ..Given the design of the project, which involves a considerable commitment on the part of both patients and their family members, we are impressed by the positive response of these women...
  27. ncbi request reprint P53 protein accumulation in non-invasive lesions surrounding p53 mutation positive invasive breast cancers
    S J Done
    Department of Laboratory Medicine, Mount Sinai Hospital, The University of Toronto, Ontario, Canada
    Breast Cancer Res Treat 65:111-8. 2001
    ..In contrast, there is no evidence that epithelial hyperplasia or epithelial cells of the terminal duct lobular unit harbor the same mutations as their associated invasive carcinoma...
  28. ncbi request reprint Fine structure analysis of the Chinese hamster AS gene encoding asparagine synthetase
    I L Andrulis
    Department of Research, Mt Sinai Hospital, Toronto, Ontario, Canada
    Gene 80:75-85. 1989
    ..The 5' flanking sequences were highly G + C-rich and, like other housekeeping genes, lacked TATA and CAAT boxes...
  29. ncbi request reprint Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas
    J S Wunder
    Department of Surgery, University of Toronto, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Canada
    Oncogene 18:783-8. 1999
    ..The different patterns of gene amplification and overexpression of CDK4, SAS and MDM2 in parosteal and intramedullary osteosarcomas may help explain the disparity in the biological behaviour of these two types of osteosarcoma...
  30. pmc Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers
    K A Schrader
    Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
    J Med Genet 48:64-8. 2011
    ..Germline mutations in CDH1 are associated with hereditary diffuse gastric cancer; lobular breast cancer also occurs excessively in families with such condition...
  31. pmc Identification and characterization of missense alterations in the BRCA1 associated RING domain (BARD1) gene in breast and ovarian cancer
    M K Sauer
    Fred A Litwin Center for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, M5G 1X5, Canada
    J Med Genet 42:633-8. 2005
    ..BARD1 is required for S phase progression, contact inhibition and normal nuclear division, as well as for BRCA1 independent, p53 dependent apoptosis...
  32. ncbi request reprint MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma
    K Eppert
    Division of Gastroenterology, The Hospital for Sick Children, Toronto, Ontario, Canada
    Cell 86:543-52. 1996
    ..These findings suggest that MADR2 is a tumor suppressor and that mutations acquired in colorectal carcinomas may function to disrupt TGFbeta signaling...
  33. ncbi request reprint Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer
    S Mousses
    Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
    Hum Mol Genet 4:1089-92. 1995
    ..006). These data suggest that the occurrence of the variants may have a direct effect on tumor development and may, in some cases, be incompatible with p53 mutations...
  34. pmc Individual and family characteristics associated with protein truncating BRCA1 and BRCA2 mutations in an Ontario population based series from the Cooperative Family Registry for Breast Cancer Studies
    H Ozcelik
    J Med Genet 40:e91. 2003
  35. ncbi request reprint Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T>G and c.1066-6T>G (IVS10-6T>G) from the Breast Cancer Family Registry
    J L Bernstein
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Hum Mutat 27:1122-8. 2006
    ....
  36. pmc Isolation of human cDNAs for asparagine synthetase and expression in Jensen rat sarcoma cells
    I L Andrulis
    Mol Cell Biol 7:2435-43. 1987
    ..Treatment of these transferant cell lines with 5-azacytidine greatly increased the expression of asparagine synthetase mRNA, protein, and activity...
  37. ncbi request reprint Validation study of the LAMBDA model for predicting the BRCA1 or BRCA2 mutation carrier status of North American Ashkenazi Jewish women
    C Apicella
    Centre for Molecular, Environmental, Analytic and Genetic Epidemiology, The University of Melbourne, Victoria, Australia
    Clin Genet 72:87-97. 2007
    ..Therefore, LAMBDA is comparable to BRCAPRO for ranking AJ women according to their probability of being a BRCA1 or BRCA2 mutation carrier and is more accurate than brcapro which substantially overpredicts carriers in this population...